T Cell Reconstitution in Allogeneic Haematopoietic Stem Cell Transplantation: Prognostic Significance of Plasma Interleukin-7
Overview
Authors
Affiliations
Infections and acute graft-versus-host disease (aGVHD) are major causes of treatment-related mortality and morbidity following allogeneic haematopoietic stem cell transplantation (HSCT). Both complications depend on reconstitution of the T-lymphocyte population based on donor T cells. Although it is well established that Interleukin-7 (IL-7) is a cytokine essential for de novo T cell development in the thymus and homoeostatic peripheral expansion of T cells, associations between circulating levels of IL-7 and T cell reconstitution following HSCT have not been investigated previously. We prospectively measured IL-7 levels in 81 patients undergoing myeloablative HSCT with either sibling donor or an unrelated donor. Plasma IL-7 levels peaked at day +7 post-transplant (1.3-82.4 pg/ml), at the time of maximal lymphopaenia. In multivariate analysis, peak levels of IL-7 were significantly higher in patients treated with anti-thymocyte globulin (ATG) compared with those not treated with ATG (P = 0.0079). IL-7 levels at day +7 were negatively associated with T cell counts at day +30 to +60 (at day +60: CD3(+) : β = -10.6 × 10(6) cells/l, P = 0.0030; CD8(+) : β = -8.4 × 10(6) cells/l, P = 0.061; CD4(+) : β = -2.1 × 10(6) cells/l, P = 0.062) in multivariate analyses. In adults, high IL-7 levels were associated with increased risk of grade II-IV aGVHD (OR = 5.4, P = 0.036) and reduced overall survival (P = 0.046). The present data indicate that high plasma levels of IL-7 in the early post-transplant period are predictive for slow T cell reconstitution, increased risk of aGVHD and increased mortality following HSCT.
Molgaard K, Kielsen K, Ifversen M, Met O, Marie Svane I, Muller K Front Immunol. 2024; 14:1327977.
PMID: 38268913 PMC: 10806108. DOI: 10.3389/fimmu.2023.1327977.
Ampuero S, Bahamonde G, Tempio F, Garmendia M, Ruiz M, Pizarro R Sci Rep. 2022; 12(1):13145.
PMID: 35907923 PMC: 9339003. DOI: 10.1038/s41598-022-13063-x.
Ingham A, Kielsen K, Cilieborg M, Lund O, Holmes S, Aarestrup F Microbiome. 2019; 7(1):131.
PMID: 31519210 PMC: 6744702. DOI: 10.1186/s40168-019-0745-z.
Kammersgaard M, Kielsen K, Heilmann C, Ifversen M, Muller K Bone Marrow Transplant. 2019; 54(9):1406-1418.
PMID: 30683907 PMC: 6760545. DOI: 10.1038/s41409-018-0426-8.
Carty F, Corbett J, Cunha J, Reading J, Tree T, Ting A Front Immunol. 2018; 9:645.
PMID: 29740426 PMC: 5925221. DOI: 10.3389/fimmu.2018.00645.